

# Construction of Nontoxigenic Mutants of Nonproteolytic *Clostridium botulinum* NCTC 11219 by Insertional Mutagenesis and Gene Replacement

# Charlien Clauwers,<sup>a</sup> Kristof Vanoirbeek,<sup>a</sup> Laurence Delbrassinne,<sup>b</sup> Chris W. Michiels<sup>a</sup>

Laboratory of Food Microbiology and Leuven Food Science and Nutrition Research Centre (LFoRCe), KU Leuven, Leuven, Belgium<sup>a</sup>; National Reference Centre (NRC) C. botulinum & C. perfringens, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium<sup>b</sup>

## ABSTRACT

Group II nonproteolytic *Clostridium botulinum* (gIICb) strains are an important concern for the safety of minimally processed ready-to-eat foods, because they can grow and produce botulinum neurotoxin during refrigerated storage. The principles of control of gIICb by conventional food processing and preservation methods have been well investigated and translated into guide-lines for the food industry; in contrast, the effectiveness of emerging processing and preservation techniques has been poorly documented. The reason is that experimental studies with *C. botulinum* are cumbersome because of biosafety and biosecurity concerns. In the present work, we report the construction of two nontoxigenic derivatives of the type E gIICb strain NCTC 11219. In the first strain, the botulinum toxin gene (*bont/E*) was insertionally inactivated with a retargeted intron using the Clos-Tron system. In the second strain, *bont/E* was exchanged for an erythromycin resistance gene using a new gene replacement strategy that makes use of *pyrE* as a bidirectional selection marker. Growth under optimal and stressed conditions, sporulation efficiency, and spore heat resistance of the mutants were unaltered, except for small differences in spore heat resistance at 70°C and in growth at 2.3% NaCl. The mutants described in this work provide a safe alternative for basic research as well as for food challenge and process validation studies with gIICb. In addition, this work expands the clostridial genetic toolbox with a new gene replacement method that can be applied to replace any gene in gIICb and other clostridia.

#### IMPORTANCE

The nontoxigenic mutants described in this work provide a safe alternative for basic research as well as for food challenge and process validation studies with psychrotrophic *Clostridium botulinum*. In addition, this work expands the clostridial genetic toolbox with a new gene replacement method that can be applied to replace any gene in clostridia.

**B**otulism, caused by the botulinum neurotoxin (BoNT) produced by *Clostridium botulinum*, is a rare but severe paralytic illness in humans and animals. Botulinum toxins are 150-kDa proteins with zinc endopeptidase activity, consisting of two subunits, a 100-kDa heavy chain and a 50-kDa light chain. The heavy chain is responsible for binding and translocation of the light chain into the cytosol of neuronal cells, whereas the light chain cleaves SNARE proteins that are involved in the docking of acetylcholine-containing vesicles and fusion to the presynaptic membrane. When the SNARE proteins are cleaved, neurotransmitter release is inhibited, leading to the paralysis of the corresponding muscle (1, 2).

*C. botulinum* is a strictly anaerobic bacterium that thrives in decaying organic matter in soils and sediments of ponds, lakes, and oceans. It also forms dormant endospores that are highly resilient to hostile conditions and therefore can be found widespread in the environment. These spores may contaminate foods via raw materials or other sources, possibly leading to food-borne botulism when they are not eliminated by processing and when their outgrowth is not controlled (3, 4, 5, 6, 7). *C. botulinum* is divided into four distinct groups (I to IV) based on phylogenetic and physiological characteristics, of which only group I and II typically are associated with human botulism. Group I *C. botulinum* consists of proteolytic mesophilic strains producing toxin types A, B, and/or F. These strains form heat-resistant spores and are the main target for the so-called botulinum cook, the process used in canning of low-acid foods (121°C for 3 min or equivalent).

Group II *C. botulinum* (gIICb) comprises nonproteolytic strains producing toxin types B, E, or F, which are saccharolytic and psychrotrophic (with minimum growth temperatures of 3°C) and whose spores are less heat resistant than those of group I (8). In the food industry, gIICb is a major concern for the safety of minimally processed, chilled ready-to-eat foods with an extended shelf life (REPFEDs), because spores surviving the mild processing treatments subsequently may germinate, grow, and produce toxin during refrigerated storage (6, 7, 9, 10, 11). The combination of the heat resistance of its spores and the ability to grow under refrigeration conditions makes this pathogen the main target pathogen that must be controlled in these foods. Guidelines for the control of this hazard in the food industry were developed more than 2 decades ago, requiring either a 6-decimal (6-D) reduction of the spores by heat treatment (90°C for 10 min or equivalent) or the

Received 14 November 2015 Accepted 9 March 2016

Accepted manuscript posted online 18 March 2016

**Citation** Clauwers C, Vanoirbeek K, Delbrassinne L, Michiels CW. 2016. Construction of nontoxigenic mutants of nonproteolytic *Clostridium botulinum* NCTC 11219 by insertional mutagenesis and gene replacement. Appl Environ Microbiol 82:3100–3108. doi:10.1128/AEM.03703-15.

Editor: C. M. Dozois, INRS-Institut Armand-Frappier

Address correspondence to Chris W. Michiels, chris.michiels@biw.kuleuven.be. Copyright © 2016, American Society for Microbiology. All Rights Reserved. control of outgrowth by limitation of the refrigerated storage time to <10 days, inclusion of  $\geq$ 3.5% NaCl and  $\geq$ 100 ppm nitrite, acidifying to pH  $\leq$  5.0, or an appropriate combination of these or additional hurdles (11, 12). However, the increasing consumer demand for fresh-tasting, healthy ready-to-eat foods that have been minimally processed and contain less salt and no artificial preservatives yet have a long shelf-life represents a challenge for the food industry in view of these botulinum safety guidelines (10, 11, 12). Furthermore, novel food processing and preservation technologies (e.g., high-pressure or pulsed electric field treatment and natural preservatives) have found their way to commercial food production, but data regarding their efficiency in controlling gIICb is scarce or lacking (13, 14, 15, 16, 17). This is in sharp contrast to the attention given in this context to other pathogens, like Listeria monocytogenes, Salmonella, and enterohemorrhagic Escherichia coli. The main reason for this paucity of data is that C. botulinum studies are subject to important biosafety and bioterrorism restrictions and because their culture requires strict anoxic conditions. One possible approach to circumvent these difficulties is the use of nonpathogenic surrogate organisms. For example, C. sporogenes has been widely used as a surrogate for proteolytic C. botulinum in studies on thermal processing of low-acid shelf-stable foods (18). However, a suitable validated surrogate for gIICb has been lacking to date. Recently, Parker et al. (19) studied previously isolated natural nontoxigenic Clostridium species that could be used as surrogates for gIICb. Two out of the three strains analyzed showed equal or faster growth than toxigenic gIICb under most (but not all) stress conditions (low temperature, reduced pH, and water activity  $[a_w]$ ), making them potentially useful for challenge studies with refrigerated foods, at least under some conditions. However, the spores of the three strains had lower heat resistance than some gIICb strains and could not be used for the validation of heating processes. Furthermore, it could not be excluded that the strains still carried bont or other toxin genes, and the (phylo)genetic relatedness of the strains to gIICb was not documented. This makes the behavior of the strains under other than the tested environmental conditions unpredictable (e.g., sensitivity to nitrite and other preservatives, sensitivity to organic acids, etc.).

As an alternative approach to develop safe strains for challenge studies and process validation, in the present work we attempted to construct nontoxic derivatives from a toxic gIICb strain by making a targeted knockout of the bont gene. The resulting derivative strains are expected to differ from their parent only in toxin production and thus to be a highly reliable alternative for challenge studies. Although the inactivation of specific genes in clostridial species has proven to be a rather difficult, slow, and inefficient task for a long time, the genetic toolbox for knockout mutagenesis has been expanding in the last few years. The Clos-Tron system, which makes use of a mobile intron that can be retargeted to a sequence of interest, has proven to be particularly efficient for insertional mutagenesis in a range of clostridial species (20), but only a few studies have used ClosTron mutagenesis in gIICb thus far (21, 22). Interestingly, ClosTron has been used to knock out the *bont* gene in both gICb and gIICb (21, 23), but the properties of the gIICb knockout strain in view of its possible usefulness for challenge or process validation studies in foods were not further investigated. Importantly, a disadvantage of ClosTron mutagenesis is that reversion to the toxigenic state by the excision of the intron from the *bont* gene cannot be excluded. For this reason, we additionally developed a method for bont deletion that makes use of *pyrE*, a gene encoding the enzyme orotate phosphoribosyltransferase, which is required for de novo uracil biosynthesis. This gene has been used before in various clostridia (C. sporogenes, C. difficile, and C. acetobutylicum) as a positive/negative selection marker. PyrE is essential for growth in the absence of uracil, while cells lacking PyrE become resistant to 5-fluoroorotic acid (5-FOA), a substrate analogue in *de novo* uracil biosynthesis that is converted to a toxic product. Therefore, cells encoding pyrE can be selected on uracil-free medium or counterselected in the presence of 5-FOA (24, 25, 26). We used this bidirectional selection to delete *bont/E* and replace it with an erythromycin resistance cassette. This study reports a targeted gene deletion in gIICb. The gene replacement strategy is novel in that it allows a singlestep selection of gene replacement by double homologous recombination and loss of the plasmid on which the donor DNA is supplied.

## MATERIALS AND METHODS

Bacterial strains and growth conditions. Cultures of C. botulinum type E NCTC 11219 (obtained from National Collection of Type Cultures, Public Health England) were routinely grown at 30°C in Trypticase peptone glucose yeast extract broth (TPGY; 50 g/liter Trypticase [BD], 5 g/liter bacteriological peptone [Oxoid], 20 g/liter yeast extract [Oxoid], 4 g/liter glucose, 1 g/liter sodium thioglycolate) and plated on reinforced clostridial medium (RCM [VWR]; 37 g/liter RCM with 15 g/liter agar), TPGY agar (TPGY broth with 15 g/liter agar), or tryptone yeast extract thioglycolate agar (TYG; 30 g/liter tryptone [Lab M], 20 g/liter yeast extract, 1 g/liter sodium thioglycolate, 15 g/liter agar). Trypticase glucose yeast broth (Bio-Rad) supplemented with 0.1% trypsin (Life Technologies) was used to grow cultures for the mouse bioassays. Uracil-deficient medium was made by replacing yeast extract in TPGY agar with 20 g/liter acidhydrolyzed casein (Lab M) (27). Clostridial vegetative cultures were manipulated and incubated in a Whitley DG250 anaerobic workstation (initial gas mixture comprised of 80% N2, 10% CO2, and 10% H2) using overnight prereduced media. E. coli strains were grown in lysogeny broth (LB; 10 g/liter tryptone, 5 g/liter yeast extract, 5 g/liter NaCl) or on LB agar (LB with 15 g/liter agar) at 37°C. E. coli DH5 $\alpha$  was used for cloning and maintenance of plasmids, while E. coli CA434 (HB101 containing plasmid R702 [28]) was used as a conjugation donor. Media were supplemented with the following antibiotics (Applichem): thiamphenicol (Tm; 15 µg/ml in agar, 7.5 µg/ml in broth) and erythromycin (Em; 2.5 µg/ml) for C. botulinum, as well as cycloserine (Cy; 250 µg/ml) and chloramphenicol (Cm; 25 µg/ml in agar, 12.5 µg/ml in broth) for E. coli. 5-Fluoroorotic acid (5-FOA; 500 µg/ml [Manchester Organics]) was used for the screening of uracil auxotrophs.

**Sporulation and purification of spore crops.** Spore crops were prepared using a two-phase sporulation medium as described before, with minor adjustments (29). First, a single colony was inoculated in 1 ml TPGY broth at 30°C. After 24 h of growth, this culture was added to a two-phase medium consisting of 4 ml distilled deoxygenated water over solid sporulation medium (3 g cooked meat medium [Oxoid], 0.03 g glucose, 0.45 g agar in 30 ml water). Spores were harvested from the liquid phase after 6 days of incubation at 30°C by centrifugation (3,400 × g, 4°C, 15 min). The resulting pellet was washed four times with 0.85% sterile saline by centrifugation, concentrated 5-fold, and stored in saline at 1 to 4°C outside the anaerobic workstation.

**Construction of plasmids.** The ClosTron technology was used for the generation of an insertion mutant. This system is based on retargeting a bacterial group II intron to insert in a gene of interest (20, 30). Possible target sites in the *bont/E* gene of *C. botulinum* NCTC 11219 were identified using an intron design tool on the ClosTron website (www.clostron.com), and one site was chosen based on a high score according to the algorithm as well as proximity to the N terminus of the toxin. The plasmid

TABLE 1 PCR oligonucleotides used for cloning and construct verification

Category and primer					
name	Sequence <sup><math>c</math></sup> (5'-3')				
ClosTron					
bontE_F	CCAGGCGGTTGTCAAGAATTTTAT	$2298420^{a}$			
bontE_R	TCAAATAAATCAGGCTCTGCTCCC	$2298057^{a}$			
RAM_F	ACGCGTTATATTGATAAAAATAATAATAGTGGG				
RAM_R	ACGCGTGCGACTCATAGAATTATTTCCTCCCG				
pCD6_F	GTTGGGAGTAGTTGTGC				
pCD6_R	ATGGTATCTCATTATTGGC				
ClosTron_R	GTTTCAGACACTTTCCTCTATCGAG				
Y-linker primer	TTTCTGCTCGAATTCAAGCTTCTAACGATGTACGGGGACACATG				
$\Delta pyrE$					
pyrE_5'F	AAC <u>GGTACC</u> CCACTACGTTCTCTCTTAGAGG	246521 <sup>b</sup>			
pyrE_5'R	AAC <u>GGATCC</u> TGAGTTTAAGGTTTTTAGTTGG	247564 <sup>b</sup>			
pyrE_3'F	CAT <u>GGATCC</u> TCCTCCCAAATTTCATAATGT	$248312^{b}$			
pyrE_3'R	CAT <u>CTCGAG</u> TGTTTTATGCTGTGGTCCTG	249436 <sup>b</sup>			
pyrE_5'Fb	CCAACTTTATCAAAAGCTCAG	246369 <sup>b</sup>			
pyrE_3'Rb	CTAATACAGGAAAGCATGGC	249503 <sup>b</sup>			
pMTL84151_mcsF	AGGAAACAGCTATGACCG				
pMTL84151_mcsR	GACGTTGTAAAACGACGG				
$\Delta bont E$					
pyrE11219_F	AGG <u>CATATG</u> GAAGCATATAAAAAAGAG	$248264^{b}$			
pyrE11219_R	CTT <u>GAGCTC</u> CTACTTAGCACCATATTC	247627 <sup>b</sup>			
bontE_5'F	TAA <u>GGTACC</u> GTTATTGGAGATACATCCGG	2299564 <sup>a</sup>			
bontE_5'R	TAA <u>GGATCC</u> TGGCATATACAGCATCTCC	2298522 <sup>a</sup>			
bontE_3'F	TAA <u>GGATCC</u> AGAGATCATACAAACAGCAATGG	2294800 <sup>a</sup>			
bontE_3'R	TAA <u>CTCGAG</u> CTATTCGAGAGAGCATTGGTCG	2293583 <sup>a</sup>			
upbontE_F	GAACTACTTATAAAAGAACAAACCTCACC	$2299627^{a}$			
downbontE_R	GAATGGATATCTTAGGATAATCATTCCAC	2293466 <sup>a</sup>			
pMTL83353_F	GAG <u>CCTGCAGG</u> ATAAAAAATTGTAG				
pMTL82254ermB_F	GTT <u>GGATCC</u> GAAGCAAACTTAAGAGTGTG				
pMTL82254ermB_R	TAC <u>GGATCC</u> ACATTCCCTTTAGTAACGTG				

<sup>a</sup> The primer coordinates for NCTC 11219 are based on accession number JXMR01000001.

<sup>b</sup> The primer coordinates for NCTC 11219 are based on accession number JXMR01000004.

<sup>c</sup> Restriction sites are underlined: KpnI (GGTACC), BamHI (GGATCC), XhoI (CTCGAG), NdeI (CATATG), SacI (GAGCTC), and SbfI (CCTGCAGG).

pMTL007C-E2:Cbo:*bontE*-211a, containing the intron flanked by the specific targeting sequences (GGTCATAATAACTACTATCTCCATTTT TTA<intron>CTAATTATTTACAAA), was obtained from DNA 2.0 Inc. (Menlo Park, California, USA).

The second knockout strategy consisted of an allelic exchange of *bont/E* with *ermB*, an Em resistance gene. A novel three-step strategy was designed, with each step requiring a specific plasmid construct. Oligonucleotide primers used in these constructions are listed in Table 1 and were obtained from Integrated DNA Technologies (Heverlee, Belgium). Constructs were routinely transferred to *E. coli* DH5 $\alpha$  by electroporation and verified by sequencing before further use. The first plasmid construct was used to generate a *pyrE* deletion (locus tag SR42\_16845) in strain NTCT 11219. To this end, flanking loci of *pyrE* were cloned in pMTL84151 (31)

to yield pMTL84151\_*pyr5' pyr3'*. More specifically, the 5' fragment (1,086 bp) was amplified from genomic DNA (gDNA) of NCTC 11219 with primers pyrE\_5'F/pyrE\_5'R, and the 3' fragment (1,164 bp) was amplified with primers pyrE\_3'F/pyrE\_3'R. Amplicons were restricted with KpnI/BamHI and BamHI/XhoI, respectively, ligated end to end in pMTL84151 opened with KpnI and XhoI, and electroporated to *E. coli* DH5 $\alpha$ . Second, the plasmid pMTL84151\_ $\Delta$ bont, used to replace bont/*E* with *ermB*, was constructed as illustrated in Fig. 1. Flanking loci (5' locus, 1,080 bp; 3' locus, 1,261 bp) of *bont/E* first were cloned in pMTL84151 using primers bontE\_5'F/bontE\_5'R and bontE\_3'F/bontE\_3'R for amplification. These loci include the first two codons of *bont/E* in the 5' fragment and the last 16 codons in the 3' fragment. After restriction of the PCR products with KpnI/BamHI and BamHI/XhoI, respectively, the 5'



**FIG 1** Scheme showing the different fragments cloned between SbfI and AscI restriction sites of shuttle vector pMTL84151 (Tm<sup>r</sup>) to create pMTL84151\_ $\Delta bont$  (Tm<sup>r</sup> Em<sup>r</sup>), which was used for replacing the *bont/E* gene with an *ermB* marker. The p<sub>fdx</sub> promoter (bent arrow) was derived from pMTL83353 and drives the expression of *pyrE*, which was amplified from gDNA of NCTC 11219. The 5' and 3' fragments of *bont/E* also were amplified from NCTC 11219 gDNA and flank *ermB* derived from pMTL8254.

and 3' fragments were ligated end to end in pMTL84151 opened with KpnI and XhoI. Subsequently, ermB (amplified from pMTL82254 with pMTL82254ermB\_F/pMTL82254ermB\_R and restricted at both ends with BamHI) was inserted in the BamHI site of this plasmid, resulting in pMTL84151\_5'bont\_ermB\_3'bont. In addition, wild-type (WT) pyrE of NCTC 11219 (675 bp) was amplified from start to stop codons with primers pyrE11219\_F/pyrE11219\_R, restricted with NdeI/SacI, and placed after promoter  $\mathbf{p}_{\rm fdx}$  in pMTL83353 opened with the same enzymes.  $\mathbf{p}_{\rm fdx}$  was used to drive pyrE expression, because pyrE is located at the end of an operon in NCTC 11219 and could not be amplified simply with its native promoter. Here, the fragment containing p<sub>fdx</sub> and pyrE was amplified with pMTL83353\_F/pyrE11219\_R, digested with SbfI and SacI, and cloned in pMTL84151\_5'bont\_erm\_3'bont restricted with the same enzymes. This resulted in the plasmid pMTL84151\_ $\Delta bont$ . A third plasmid was designated pMTL84151\_WTpyr and was used for restoring the pyrE deletion back to wild-type status. This was created by cloning a pyrE amplicon with its 5' and 3' flanking regions (2,956 bp) generated with primers pyrE\_5'F/ pyrE\_3'R and restricted with KpnI and XhoI into pMTL84151 cleaved with the same enzymes. A promoter is absent from this construct; thus, *pyrE* is not expressed on the plasmid.

**Mating.** Each of the four plasmid constructs described above was introduced into *E. coli* CA434 by electroporation and selecting Cm<sup>r</sup> transformants. For plasmid transfer to *C. botulinum* NCTC 11219, 1 ml of an overnight LB culture of *E. coli* donor containing the appropriate plasmid was centrifuged. The pellet was washed with PBS (phosphate-buffered saline; 8 g/liter NaCl, 0.2 g/liter KCl, 1.44 g/liter Na<sub>2</sub>HPO<sub>4</sub>, 0.24 g/liter KH<sub>2</sub>PO<sub>4</sub>, pH adjusted with HCl to 7.4) and taken to the anaerobic workstation. The pellet next was resuspended in 200 µl of NCTC 11219 recipient grown for 24 h in TPGY broth, after which the mixture was spread on a cellulose acetate filter (pore size, 0.45 µm) on nonselective TYG agar. After 24 h of incubation at 30°C, the cells were washed off the filter with 1 ml PBS, and 200 µl was plated on selective RCM plates (Tm for resistance encoded by the plasmid, Cy against *E. coli* donor). Colonies appearing within 3 days were restreaked to purity on the same selective medium.

**Isolation and verification of** *bont/E* **ClosTron insertion mutant.** To confirm the transfer of the ClosTron plasmid pMTL007C-E2:Cbo:*bontE*-211a to NCTC 11219, Tm<sup>r</sup> colonies were purified after mating and analyzed by PCR using primers RAM\_F/RAM\_R. Subsequently, transconjugants were streaked on RCM supplemented with Em, and well-developed colonies appearing within 3 days were restreaked on the same medium for purification. PCR and sequence analysis with primers bontE\_F/bontE\_R were performed to verify successful intron insertion in *bont/E*. Individual colonies from a verified clone then were screened for Tm sensitivity, indicating the loss of the ClosTron plasmid, which was confirmed here by PCR using primers pCD6\_F/pCD6\_R.

To investigate whether only one insertion event took place, the Y-linker PCR described by Kwon and Ricke (32) was used. In this method, gDNA of the ClosTron mutant is restricted to completion with NlaIII and ligated to a Y-shaped linker, generated by mixing two oligonucleotides that are complementary only at one end. The complementary parts of these oligonucleotides form the stalk of the linker, which has a 3' CATG overhang that stocks to the NlaIII chromosomal DNA ends. The non-complementary parts of the oligonucleotides form the Y-linker arms. PCR then is conducted on the ligation mixture with a ClosTron-specific primer (ClosTron\_R) and a Y-linker primer with a sequence identical, not complementary, to the sequence of one of the arms. The Y-linker primer can anneal and a PCR product is formed only when the ClosTron\_R primer extends DNA synthesis during the first PCR cycle into the Y-linker arm. Consequently, the two primers selectively amplify all fragments in the genome containing the ClosTron insert.

**Isolation and verification of** *bont/E* **deletion mutant.** After conjugation of pMTL84151-*pyr5' pyr3'* to NCTC 11219, transconjugants were streaked on RCM supplemented with 5-FOA to select for PyrE-deficient mutants generated by double homologous recombination between the plasmid-based *pyrE*-flanking fragments and the corresponding chromo-

somal sequences. Deletion was confirmed by PCR and sequence analysis with primers pyrE\_5'Fb/pyrE\_3'Rb, which anneal outside the homologous fragments involved in recombination. Further, a clone from which the plasmid was cured was isolated by screening for Tm sensitivity. The NCTC 11219  $\Delta pyrE$  mutant next was mated with *E. coli* CA434 containing pMTL84151\_ $\Delta bont$ . Transconjugants were streaked on RCM supplemented with Em and 5-FOA to select for clones in which double homologous recombination as well as the loss of the plasmid had occurred. Plasmid loss was confirmed by the Tm sensitivity of the clones. PCR and sequence analysis with primers upbontE\_F/downbontE\_R, annealing outside the homologous fragments, were performed to confirm that *bont/E* was deleted and replaced by *ermB*. Finally, the wild-type *pyrE* gene was restored by first conjugating pMTL84151-WTpyr to the NCTC 11219  $\Delta pyrE \Delta bontE::ermB$  mutant and subsequently propagating one transconjugant in liquid TPGY medium for about 60 generations and then plating on uracil-deficient medium. Only clones in which the chromosomal pyrE gene is restored by allelic exchange with the plasmid-based promoterless pyrE grow well on these plates. One such clone, confirmed by PCR and sequence analysis to be identical to the wild type in the *pyrE* locus and from which the plasmid was cured as explained before, was isolated and designated the NCTC 11219  $\Delta bontE::ermB$  mutant.

Mouse bioassays. Mouse bioassays were performed for the detection of active botulinum toxin in clostridial cultures. The assays were performed with NCTC 11219 *bontE*211a::CT and NCTC 11219  $\Delta pyrE$ ∆bontE::ermB bont/E knockout strains and with the corresponding positive-control strains NCTC 11219 wild type and NCTC 11219  $\Delta pyrE$  mutant, respectively. Supernatants from 5-day cultures of the strains in Trypticase glucose yeast broth supplemented with trypsin at 30°C were used for toxin testing. A seroneutralization test using anti-E antitoxin, which specifically neutralizes the toxic effects of BoNT/E, was included. Neutralized (i.e., mixed with antitoxin) and untreated filtered supernatants were injected intraperitoneally in mice for evaluating the toxicity. Two animals were used per sample. Mice were observed at regular intervals for a period of 4 days for signs of botulism (ruffling of the fur, hypotonic abdomen, wasp-waist, difficulty in breathing, weakness of limbs, and total paralysis) or death. Typical paralysis and/or death of the mice with prevention of these effects by the administration of antitoxin was established a positive test for BoNT/E.

Phenotypical analysis of wild-type NCTC 11219 and NCTC 11219 bont/E mutants. (i) Unstressed growth. Wild-type *C. botulinum* NCTC 11219 and *bontE*211a::CT and  $\Delta bontE::ermB$  mutants were inoculated from single colonies in 1 ml TPGY broth in triplicate and incubated for 24 h at 30°C. The stationary-phase cultures were diluted  $5 \times 10^3$ -fold in 50 ml TPGY (equal to time zero) and incubated at 30°C. Cell numbers were determined by plate counting on TPGY agar every 2 h during 16 h and again 8 h later.

(ii) Stressed growth. Overnight cultures of the wild type and mutants were streaked 6-fold on RCM plates with different pHs (5.7, 5.5, 5.2, and 4.9; adjusted with HCl and measured before and after autoclaving) or NaCl content (1.9%, 2.1%, 2.3%, and 2.5%; taking into account that 0.5% NaCl is already present in RCM). The plates were incubated at 30°C in an anaerobic workstation, and colony formation was observed macroscopically for several days. Growth at lower temperatures was analyzed in 6-fold by streaking single colonies that were pregrown at 12°C on RCM plates and incubating in AnaeroGen bags (Oxoid) at 8°C and 12°C. Colony formation was observed daily.

(iii) Heat resistance of spores. Spore crops were made in triplicate from different colonies per strain and used within 2 weeks for this experiment. The initial spore count was determined by plate counting on TPGY after a heat treatment to inactivate remaining vegetative cells (65°C, 10 min), but samples that were not preheated were used for the heat inactivation experiment. Heat treatments were conducted in a heating block at 70°C, 73°C, 90°C, and 93°C. At different time points, samples were taken and cooled immediately to stop inactivation, diluted in 0.85% NaCl, plated on TPGY, and incubated at 30°C for colony counting. For the



FIG 2 (A) Schematic representation of *bont/E* with its upstream and downstream genes in *C. botulinum* NCTC 11219. Locus tags for all genes are shown. (B) Position of the ClosTron insert after the 211th base of the *bont/E* open reading frame in the NCTC 11219 *bontE*211a::CT mutant, with *ermB* positioned antisense to *bont/E*. Also shown are primers bontE\_F/bontE\_R, annealing up- and downstream of the ClosTron target site, and primers upbontE\_F/downbontE\_R, annealing outside the loci used in double homologous recombination to delete *bont/E*. (C) NCTC 11219  $\Delta bontE::ermB$  mutant with *bont/E* deleted and replaced by *ermB*, confirmed by PCR using primers upbontE\_F/downbontE\_R. The positions of the cloning primers bontE\_5'F/bontE\_5'R and bontE\_3'F/bontE\_3'R, used for construction of pMTL84151\_ $\Delta bont$ , also are indicated.

treatments at 90°C and 93°C, lysozyme (10  $\mu$ g/ml; Carl Roth GmbH) was added to the plating medium.

**Statistical analysis.** To statistically assess the equivalence of unstressed growth, spore yield, and spore heat resistance between the wild type and the two *bont/E* mutants, the two-tailed unpaired Student's *t* test was used with a significance level of 0.05. Since growth at low temperature was analyzed in a time-to-colony-formation experiment, a logistic regression model was fitted using the day, temperature, and strain as predictor variables. The proposed model was highly significant (*P* value of <0.001 by the whole-model likelihood ratio test; generalized  $R^2$  of 0.9063) and showed no lack of fit (*P* value of ~1 by the lack-of-fit likelihood ratio test), indicating it was suitable for testing the individual parameters.

# **RESULTS AND DISCUSSION**

*C. botulinum* NCTC 11219 is a group II type E strain isolated in 1979 from salmon after an outbreak of human botulism (33), of which we previously reported the genome sequence of four contigs (GenBank accession no. JXMR01000001 to JXMR01000004) (34). Here, we used this strain for the construction of atoxigenic mutants. The ClosTron system was used for the insertional inactivation of the *bont/E* gene, whereas a new approach based on double homologous recombination using the selection markers *pyrE* and *ermB* was designed to create a *bont/E* deletion.

**Construction of** *C. botulinum* NCTC 11219 *bontE*211a::CT insertion mutant. Plasmid pMTL007C-E2:Cbo:*bontE*-211a, containing an intron retargeted to insert into *bont/E*, was transferred by conjugation to NCTC 11219. Since the intron contains a retrotransposition-activated marker (RAM) based on the *ermB* gene, the successful insertion of the intron in the genome is selectable by the expression of Em resistance. Em<sup>r</sup> clones were picked up and analyzed by PCR and sequence analysis. The intron was correctly located in one clone at position 211 in the *bont/E* open reading frame with an antisense orientation of *ermB* relative to *bont/E* (Fig. 2 and 3, lanes 2 and 3). Further analyzing this clone by Y-linker PCR and sequencing of the PCR product confirmed that only a

single intron was present in the genome. The efficiency of the different steps in the ClosTron mutagenesis procedure was rather low. For the conjugation of the ClosTron plasmid to NCTC 11219, several attempts were needed to obtain only two transconjugants. Similarly, several clones of transconjugants had to be restreaked to obtain 15 Em<sup>r</sup> colonies, and only one of these had the correct intron insertion. This confirms earlier statements in the literature that *C. botulinum* is less genetically tractable than most other clostridia (21, 35).

Construction of *C. botulinum* NCTC 11219  $\Delta bontE::ermB$  deletion mutant. A deletion strategy to knock out *bont/E* was developed by combining different genetic tools that have not yet



FIG 3 PCR analysis of different strain constructs. Lanes 1 and 8, molecular weight marker (GeneRuler from Life Technologies); lane 2, NCTC 11219 with *bont/E* fragment amplified with primers bontE\_F/bontE\_R (expected size, 410 bp); lane 3, NCTC 11219 *bontE*211a::CT mutant with *bont/E* fragment with ClosTron insertion amplified with primers bontE\_F/bontE\_R (expected size, 2,008 bp); lane 4, NCTC 11219 with *pyrE* region amplified with primers pyrE\_5Fb/pyrE\_3Rb (expected size, 3,174 bp); lane 5, NCTC 11219 Δ*pyrE* mutant with *bont/E* region amplified with primers pyrE\_5Fb/pyrE\_3Rb (expected size, 2,474 bp); lane 6, NCTC 11219 Δ*pyrE* mutant with *bont/E* region amplified with primers upbontE\_F/downbontE\_R (expected size, 6,218 bp); lane 7, NCTC 11219 Δ*bontE::ermB* mutant with *bont/E* region amplified with primers upbontE\_F/downbontE\_R (expected size, 3,449 bp).

been used in gIICb, despite their success in other clostridia. Since effective suicide plasmids have not yet been described for C. botulinum, and given the reported low frequency of DNA transfer into gIICb, we chose to make use of pseudosuicide plasmids for conjugation (30, 36). These plasmids autonomously replicate but are segregationally unstable, providing the advantage of being lost more rapidly in the absence of selection after successful conjugation. A set of modular shuttle vectors, the pMTL80000 series, carrying four different Gram-positive replicons was constructed by Heap et al. (31) for use in the clostridia. We selected pMTL84151 with the pCD6 replicon from this set, since this plasmid has the lowest stability in groups I and II C. botulinum (31 and unpublished results). Another key element in the knockout strategy was the use of the *pyrE* gene as a bidirectional selection marker. First, pyrE was deleted from NCTC 11219, resulting in a 5-FOA-resistant and uracil auxotrophic strain (Fig. 3, lanes 4 and 5). The obtained  $\Delta pyrE$  mutant then was used as the background to delete *bont/E* and replace it with an *ermB* marker. This was achieved by first conjugating pMTL84151  $\Delta bont$  (Fig. 1) to the  $\Delta pyrE$  mutant and selecting for Tm resistance and then streaking a transconjugant on medium containing both Em and 5-FOA. Since the plasmid expresses pyrE in trans, 5-FOA selects for its loss. Further, clones that lost the plasmid can remain resistant to Em only when the *ermB* gene was exchanged with the *bont/E* gene by double homologous recombination. Although this procedure selects for two events simultaneously, the frequency was sufficient to allow the isolation of several colonies from a single streak. Obviously, the efficiency benefits from the low segregational stability of the plasmid. The loss of the plasmid was confirmed by the loss of Tm resistance, and PCR and sequence analysis confirmed the replacement of *bont/E* by *ermB* (Fig. 2 and 3, lanes 6 and 7).

Finally, the *pyrE* deletion strain was restored to wild-type status by inserting *pyrE* and its flanking regions back into the chromosome by double homologous recombination with pMTL84151\_WTpyr. To this end, the plasmid first was conjugated to the NCTC 11219  $\Delta pyrE \Delta bontE::ermB$  mutant. The Tm<sup>r</sup> transconjugants remained resistant to 5-FOA, which confirmed that *pyrE* was not expressed on pMTL84151\_WTpyr. Since *pyrE* was cloned without its promoter (which is further upstream of the pyr operon) on this plasmid, there is no leaky expression from plasmid promoters. In line with this observation, the transconjugants did not grow when they were plated on uracil-deficient medium, except for some rare colonies which showed normal growth when restreaked on the same medium. From these, subclones having lost the plasmid with a Tm<sup>s</sup> phenotype were isolated. These were confirmed to have a wild-type chromosomal pyrE allele and were designated the NCTC 11219  $\Delta bontE::ermB$  strain.

**Mouse bioassays.** The presence of BoNT/E in culture supernatants of the NCTC 11219 wild type and the  $\Delta pyrE$  strain was confirmed, whereas no active toxin was detected for the *bont/E* insertion and deletion mutants. All mice injected with supernatant of wild-type and  $\Delta pyrE$  strains died within a day, while mice injected with supernatants of the mutants or supernatants from the *bont/E* wild-type strains mixed with antitoxin E survived until the end of observation at 4 days. Thus, the loss of toxicity in both mutants was confirmed. In addition, the seroneutralization test using anti-E antitoxin confirmed that only one neurotoxin is produced by NCTC 11219, as was already predicted from the genome sequence (34).



FIG 4 Growth in TPGY broth at 30°C of wild-type NCTC 11219, NCTC 11219 *bontE*211a::CT, and NCTC 11219 *\Delta bontE::ermB* strains determined by plate counting on TPGY. Averages  $\pm$  standard deviations are shown from three independent experiments.

Phenotypic analysis of wild-type NCTC 11219 and NCTC 11219 bont/E mutants. Nontoxic mutants of gIICb have the potential to greatly facilitate basic research and food challenge studies with this organism, provided that their properties related to growth, sporulation, survival, and inactivation are not modified due to the knockout of the *bont/E* gene. Here, we compared the growth, sporulation, and spore heat resistance of both constructed *bont/E* mutants and the wild-type NCTC 11219 strain.

(i) Unstressed growth. The growth curves of the mutants and the wild type at 30°C were very similar (Fig. 4). The DMFit software was used to determine the maximum growth rate,  $\mu_{max}$ , and the upper asymptote,  $\gamma_{end}$ . The lag phase could not be evaluated because there were not enough points available to measure this accurately. No significant differences existed between  $\mu_{max}$  and  $\gamma_{end}$  of the wild-type, ClosTron, and  $\Delta bontE$  mutant strains. The values were  $0.7 \pm 0.2$ ,  $0.5 \pm 0.1$ , and  $0.4 \pm 0.0$  (log CFU/ml)/h for  $\mu_{max}$  and  $7.8 \pm 0.3$ ,  $8.0 \pm 0.0$ , and  $8.0 \pm 0.1$  log CFU/ml for  $\gamma_{end}$ , respectively.

(ii) Stressed growth. A quantitative comparison of growth under acidic, NaCl, and low-temperature stress was performed by assessing the time to colony formation on RCM plates. On acidified RCM, results of both mutants and the wild type were identical in 6-fold streaking. Single colonies of 1 mm were visible after 24 h at pH 5.7 and after 30 h at pH 5.5, while pinpoint colonies appeared after 72 h at pH 5.2. No colonies were formed at pH 4.9 up to 5 days. Under NaCl stress, all three strains showed clear single colonies in 6-fold after 24 h at 1.9% and 2.1% NaCl. Unexpectedly, a small difference was observed at 2.3% NaCl between the  $\Delta bontE::ermB$  strain and the wild type and ClosTron mutant. Strain *AbontE::ermB* formed clear 1-mm colonies after 24 h (6fold), while those of the wild type and ClosTron mutant were pinpoint sized and reached 1 mm only after 48 h (6-fold streaking). No colonies appeared on 2.5% NaCl for any strain. The third stress condition tested was growth at low temperature. Single colonies grown at 12°C on RCM were restreaked 6-fold on RCM and then incubated at 12°C and 8°C, and the time to formation of colonies (1 mm) was registered. As opposed to the data for acid and NaCl stress, the time to colony formation at low temperature showed variability among the six replicates, as indicated in Table 2. A logistic regression model was fit on these data and showed that there was no significant effect of the strain (P value of 0.2388 by

Strain	No. of plates showing single colonies <sup><i>a</i></sup> at:					
	12°C		8°C			
	3 days	4 days	7 days	8 days	9 days	
NCTC 11219	5/6	6/6	4/6	5/6	6/6	
bontE211a::CT ∆bontE::ermB	4/6 3/6	6/6 6/6	4/6 3/6	6/6 4/6	6/6 6/6	

TABLE 2 Growth of NCTC 11219 WT, NCTC 11219 *bontE*211a::CT, and NCTC 11219  $\Delta bontE$ ::*ermB* strains on RCM plates

 $^{a}$  Single colonies were restreaked 6-fold, and the time to the formation of 1-mm colonies was noted.

effect likelihood ratio test). Therefore, it can be concluded that there is no significant difference in growth at low temperature between the three strains.

(iii) Spore production. Sporulation was performed in twophase sporulation medium and observed regularly with phasecontrast microscopy. Spore formation started within 72 h for all strains. Spore counts were determined after 6 days by plate counting after the inactivation of the vegetative cells at 65°C for 10 min. No differences were observed in spore yield between wild-type, *bontE*211a::CT, and  $\Delta bontE$ ::*ermB* strains. Spore crops used for treatments at 90°C and 93°C had yields of 7.8  $\pm$  0.1, 8.1  $\pm$  0.3, and 7.9  $\pm$  0.1 log CFU/ml, respectively. The spore crops used for heat treatments at 70°C and 73°C all had the same yield, 7.6  $\pm$  0.1 log CFU/ml.

(iv) Spore heat resistance. In the analysis of spore heat resistance, we incorporated lysozyme in the recovery medium because it is known to increase the number of survivors of gIICb spores (37, 38). This is because the cortex hydrolases, which are required for spore germination, are very heat sensitive but can be replaced with exogenous lysozyme. The inactivation curves at 90°C and 93°C showed a biphasic trend, with an initial rapid decrease of about 2 to 2.5 log, followed by a slower log-linear decrease (Fig. 5). This is in line with previous reports and has been attributed to the existence of a lysozyme-impermeable and -permeable fraction in the spore population (38, 39). The decimal reduction times (D values) were calculated only from the log-linear part, corresponding to the presumed lysozyme-permeable fraction. No differences were observed in the  $D_{90^{\circ}C}$  and  $D_{93^{\circ}C}$  between the three strains, suggesting that spore heat resistance is not affected by the inactivation of *bont/E*. In addition, we chose to report heat resistance without lysozyme in the recovery medium. This reduces the apparent heat resistance of the spores, and treatments were performed at 70°C and 73°C. Inactivation was log linear in this case (Fig. 6) and presumably correlates with the inactivation of the spore cortex hydrolases. The D70°C of the two mutants was slightly but significantly lower than that of the wild type, but no difference was found between the D70°C of both mutants mutually. In contrast, the D73°C was not different between the three strains. Together, these results indicate that spore heat resistance is unaffected in the mutants, except for a small difference at 70°C. Since this difference was observed in both the insertion and deletion mutants, it is unlikely to result from an accidental mutation unrelated to the knockout of the *bont/E* gene. One possible explanation is that the effect is due to a polar effect on one or more genes upstream or downstream of bont/E. However, given the gene context shown in Fig. 2, it is difficult to imagine how the same polar effect could exist in both mutants. Finally, it cannot be excluded that the difference is a direct consequence of the abolition of toxin production. For example, it has been demonstrated recently that there is a regulatory link between



FIG 5 Heat inactivation of spores of wild-type NCTC 11219, NCTC 11219 *bontE*211a::CT, and NCTC 11219  $\Delta bontE$ ::ermB strains at 90°C and 93°C. Averages  $\pm$  standard deviations from three independent experiments are shown, as are average D values  $\pm$  standard deviations at 90°C and 93°C derived from the linear part of the curve. A common superscript letter at the same temperature indicates that there is no significant difference.



FIG 6 Heat inactivation of spores of wild-type NCTC 11219, NCTC 11219 *bont*E211a::CT, and NCTC 11219  $\Delta bont$ E::ermB strains at 70°C and 73°C. Averages ± standard deviations from three independent experiments are shown, as well as average D values ± standard deviations at 70°C and 73°C. A common superscript letter at the same temperature indicates that there is no significant difference. Since tailing occurred after 40 min at 70°C and after 15 min at 73°C, the corresponding data are not shown or used.

sporulation and toxin production in gIICb strain Beluga via the Spo0A gene product (40).

In conclusion, two strategies were employed in this study for obtaining a gIICb surrogate in which the *bont/E* gene is inactivated. Besides the well-known ClosTron system, which generates insertional knockouts, we additionally developed a new approach based on double homologous recombination for the replacement of *bont/E* with an *ermB* cassette. Growth under unstressed and stressed conditions, sporulation, and spore heat resistance of both mutants were compared to that of wild-type NCTC 11219 and were unaffected, except for two properties where small differences were noted. Heat resistance of the spores at 70°C was slightly lower for both mutants. In addition, the growth of the deletion mutant in 2.3% NaCl was faster than for the other strains. The reason for the changes currently is unclear, and it would be interesting to investigate whether they are related to the loss of toxin production or to random mutations that have occurred during strain construction. However, since the deviations in the mutants are small compared to the natural strain-to-strain variation within gIICb, the nontoxic strains will be useful to investigate the safety of novel food processing and preservation techniques and for food challenge studies. Furthermore, the method for gene deletion developed in this work is a novel tool to construct nontoxic derivatives of type B and F gIICb strains as well as to inactivate any other gene in gIICb and other clostridia.

## ACKNOWLEDGMENTS

We thank N. P. Minton and J. T. Heap for generously providing the pMTL80000 kit and *E. coli* CA434.

#### FUNDING INFORMATION

This work was funded by Research Foundation-Flanders (G.0C77.14N) and by KU Leuven Research Fund (METH/14/03). The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

#### REFERENCES

- Turton K, Chaddock JA, Acharya KR. 2002. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 27:552–558. http://dx.doi.org/10.1016/S0968-0004(02)02177-1.
- Dolly JO, Aoki KR. 2006. The structure and mode of action of different botulinum toxins. Eur J Neurol 13:1–9. http://dx.doi.org/10.1111/j.1468 -1331.2006.01648.x.
- 3. Johannsen A. 1965. *Clostridium botulinum* type E in foods and the environment generally. J Appl Bacteriol 28:90–94.
- Bott TL, Johnson J, Jr, Foster EM, Sugiyama H. 1968. Possible origin of the high incidence of *Clostridium botulinum* type E in an inland bay (Green Bay of Lake Michigan). J Appl Bacteriol 95:1542–1547.
- 5. Dodds KL 1993. *Clostridium botulinum* in the environment, p 21–51. *In* Hauschild AHW, Dodds KL (ed), *Clostridium botulinum*: ecology and control in foods. Marcel Dekker, New York, NY.
- Hielm S, Hyytiä E, Andersin AB, Korkeala H. 1998. A high prevalence of *Clostridium botulinum* type E in Finnish freshwater and Baltic Sea sediment samples. J Appl Microbiol 84:133–137. http://dx.doi.org/10.1046/j .1365-2672.1997.00331.x.
- Hyytiä E, Hielm S, Korkeala H. 1998. Prevalence of *Clostridium botulinum* type E in Finnish fish and fishery products. Epidemiol Infect 120: 245–250. http://dx.doi.org/10.1017/S0950268898008693.
- Carter AT, Peck MW. 2015. Genomes, neurotoxins and biology of *Clostridium botulinum group* I and group II. Res Microbiol 166:303–317. http://dx.doi.org/10.1016/j.resmic.2014.10.010.
- Graham AF, Mason DR, Maxwell FJ, Peck MW. 1997. Effect of pH and NaCl on growth from spores of non-proteolytic *Clostridium botulinum* at chill temperature. Lett Appl Microbiol 24:95–100. http://dx.doi.org/10 .1046/j.1472-765X.1997.00348.x.
- 10. Lindström M, Kiviniemi K, Korkeala H. 2006. Hazard and control of

group II (non-proteolytic) *Clostridium botulinum* in modern food processing. Int J Food Microbiol 108:92–104. http://dx.doi.org/10.1016/j.ijfoodmicro.2005.11.003.

- Peck MW. 2006. Clostridium botulinum and the safety of minimally heated, chilled foods: an emerging issue? J Appl Microbiol 101:556–570. http://dx.doi.org/10.1111/j.1365-2672.2006.02987.x.
- Peck MW, Stringer SC. 2005. The safety of pasteurised in-pack chilled meat products with respect to the foodborne botulism hazard. Meat Sci 70:461–475. http://dx.doi.org/10.1016/j.meatsci.2004.07.019.
- Lenz CA, Vogel RF. 2014. Effect of sporulation medium and its divalent cation content on the heat and high pressure resistance of *Clostridium botulinum* type E spores. Food Microbiol 44:156–167. http://dx.doi.org /10.1016/j.fm.2014.05.010.
- Reddy NR, Tetzloff RC, Solomon HM, Larkin JW. 2006. Inactivation of *Clostridium botulinum* nonproteolytic type B spores by high pressure processing at moderate to elevated high temperatures. Innov Food Sci Emerg Technolog 7:169–175. http://dx.doi.org/10.1016/j.ifset.2006.03.002.
- Margosch D, Ehrmann MA, Buckow R, Heinz V, Vogel RF, Gänzle MG. 2006. High-pressure-mediated survival of *Clostridium botulinum* and *Bacillus amyloliquefaciens* endospores at high temperatures. Appl Environ Microbiol 72:3476–3481. http://dx.doi.org/10.1128/AEM.72.5.3476 -3481.2006.
- Gao YL, Ju XR. 2008. Exploiting the combined effects of high pressure and moderate heat with nisin on inactivation of *Clostridium botulinum* spores. J Microbiol Methods 72:20–28. http://dx.doi.org/10.1016/j.mimet .2007.11.003.
- 17. Bull MK, Olivier SA, van Diepenbeek RJ, Kormelink F, Chapman B. 2009. Synergistic inactivation of spores of proteolytic *Clostridium botulinum* strains by high pressure and heat is strain and product dependent. Appl Environ Microbiol 75:434–445. http://dx.doi.org/10.1128/AEM .01426-08.
- Brown JL, Tran-Dinh N, Chapman B. 2012. Clostridium sporogenes PA 3679 and its uses in the derivation of thermal processing schedules for low-acid shelf-stable foods and as a research model for proteolytic Clostridium botulinum. J Food Prot 75:779–792. http://dx.doi.org/10.4315 /0362-028X.JFP-11-391.
- Parker MD, Barrett PI, Shepherd J, Price LJ, Bull SD. 2015. Characterisation of non-toxigenic *Clostridium* spp. strains, to use as surrogates for non-proteolytic *Clostridium botulinum* in chilled food challenge testing. J Microbiol Methods 108:83–91. http://dx.doi.org/10.1016/j.mimet.2014 .11.011.
- Heap JT, Kuehne SA, Ehsaan M, Cartman ST, Cooksley CM, Scott JC, Minton NP. 2010. The ClosTron: mutagenesis in *Clostridium* refined and streamlined. J Microbiol Methods 80:49–55. http://dx.doi.org/10.1016/j .mimet.2009.10.018.
- 21. Marshall KM, Bradshaw M, Johnson EA. 2010. Conjugative botulinum neurotoxin-encoding plasmids in *Clostridium botulinum*. PLoS One 5:e11087.
- Mascher G, Derman Y, Kirk DG, Palonen E, Lindström M, Korkeala H. 2014. The CLO3403/CLO3404 two-component system of *Clostridium botulinum* E1 Beluga is important for cold shock response and growth at low temperatures. Appl Environ Microbiol 80:399–407. http://dx.doi.org /10.1128/AEM.03204-13.
- Bradshaw M, Marshall KM, Heap JT, Tepp WH, Minton NP, Johnson EA. 2010. Construction of a nontoxigenic *Clostridium botulinum* strain for food challenge studies. Appl Environ Microbiol 76:387–393. http://dx .doi.org/10.1128/AEM.02005-09.
- 24. Heap JT, Ehsaan M, Cooksley CM, Ng YK, Cartman ST, Winzer K, Minton NP. 2012. Integration of DNA into bacterial chromosomes from plasmids without a counterselection marker. Nucleic Acids Res 40:e59. http://dx.doi.org/10.1093/nar/gkr1321.

- Ng YK, Ehsaan M, Philip S, Collery MM, Janoir C, Collignon A, Cartman ST, Minton NP. 2013. Expanding the repertoire of gene tools for precise manipulation of the *Clostridium difficile* genome: allelic exchange using *pyrE* alleles. PLoS One 8:e56051. http://dx.doi.org/10.1371 /journal.pone.0056051.
- Zhang Y, Grosse-Honebrink A, Minton NP. 2015. A universal mariner transposon system for forward genetic studies in the genus *Clostridium*. PLoS One 10:e0122411. http://dx.doi.org/10.1371/journal.pone.0122411.
- Bitan-Banin G, Ortenberg R, Mevarech M. 2003. Development of a gene knockout system for the halophilic archaeon *Haloferax volcanii* by use of the *pyrE* gene. J Bacteriol 185:772–778. http://dx.doi.org/10.1128/JB.185 .3.772-778.2003.
- Williams DR, Young DI, Young M. 1990. Conjugative plasmid transfer from *Escherichia coli* to *Clostridium acetobutylicum*. J Gen Microbiol 136: 819–826. http://dx.doi.org/10.1099/00221287-136-5-819.
- Peck MW, Fairbairn DA, Lund BM. 1992. The effect of recovery medium on the estimated heat-inactivation of spores of non-proteolytic *Clostridium botulinum*. Lett Appl Microbiol 15:146–151. http://dx.doi.org/10 .1111/j.1472-765X.1992.tb00749.x.
- Heap JT, Pennington OJ, Cartman ST, Carter GP, Minton NP. 2007. The ClosTron: a universal gene knock-out system for the genus *Clostrid-ium*. J Microbiol Methods 70:452–464. http://dx.doi.org/10.1016/j.mimet .2007.05.021.
- Heap JT, Pennington OJ, Cartman ST, Minton NP. 2009. A modular system for *Clostridium* shuttle plasmids. J Microbiol Methods 78:79–85. http://dx.doi.org/10.1016/j.mimet.2009.05.004.
- Kwon YM, Ricke SC. 2000. Efficient amplification of multiple transposon-flanking sequences. J Microbiol Methods 41:195–199. http://dx .doi.org/10.1016/S0167-7012(00)00159-7.
- 33. Ball AP, Hopkinson RB, Farrell ID, Hutchison JGP, Paul R, Watson RDS, Page AJF, Parker RGF, Edwards CW, Snow M, Scott DK, Leone-Ganado A, Hastings A, Ghosh AC, Gilbert RJ. 1979. Human botulism caused by *Clostridium botulinum* type E: the Birmingham outbreak. Q J Med 48:473-491.
- 34. Clauwers C, Briers Y, Lavigne R, Michiels CW. 2015. Two complete and one draft genome sequence of nonproteolytic *Clostridium botulinum* type E strains NCTC 8266, NCTC 8550 and NCTC 11219. Genome Announc 3:e00083-15.
- 35. Davis TO, Henderson I, Brehm JK, Minton NP. 2000. Development of a transformation and gene reporter system for group II, nonproteolytic *Clostridium botulinum* type B strains. J Mol Microbiol Biotechnol **2**:59–69.
- Cartman ST, Minton NP. 2010. A mariner-based transposon system for in vivo random mutagenesis of *Clostridium difficile*. Appl Environ Microbiol 76:1103–1109. http://dx.doi.org/10.1128/AEM.02525-09.
- Alderton G, Chen JK, Ito KA. 1974. Effect of lysozyme on the recovery of heated *Clostridium botulinum* spores. Appl Environ Microbiol 27: 613–615.
- Peck MW, Fairbairn DA, Lund BM. 1993. Heat-resistance of spores of non-proteolytic *Clostridium botulinum* estimated on medium containing lysozyme. Lett Appl Microbiol 16:126–131. http://dx.doi.org/10.1111/j .1472-765X.1993.tb01376.x.
- 39. Lindström M, Nevas M, Hielm S, Lähteenmäki L, Peck MW, Korkeala H. 2003. Thermal inactivation of nonproteolytic *Clostridium botulinum* type E spores in model fish media and in vacuum-packaged hot-smoked fish products. Appl Environ Microbiol 69:4029–4036. http://dx.doi.org /10.1128/AEM.69.7.4029-4036.2003.
- 40. Mascher G, Derman Y, Mertaoja A, Virtala J, Toikka T, Korkeala H, Lindström M. 2015. Spo0A is important for sporulation and toxin production in *Clostridium botulinum*, p 29. Abstr 52nd Interagency Botulism Res Coord Comm Meet, Philadelphia, PA, 26 to 29 October 2014.